Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viatris IncVTRS · Entity 3277 | See Remarks | March 13, 2024 | March 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viatris Inc
Report date March 13, 2024 · Filed March 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 243,044 |
Reported balance
After 2024-03-13 transaction · row 1
1 source rowRow 1 · 2024-03-13 · Sale · Disposed 250,000 · Balance 243,044 F1: Represents the weighted average price of the reporting person's disposition of 250,000 shares of common stock in transactions ranging from $12.02 to $12.17. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,574 |
Reported balance
Holding disclosure · report date 2024-03-13 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,574 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average price of the reporting person's disposition of 250,000 shares of common stock in transactions ranging from $12.02 to $12.17. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mylan II B.V.
Report date November 16, 2020 · Filed November 18, 2020
Section 16 reporting ended · disclosed 2020-11-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 119,305 · Balance 0 F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy 401(k) Plan | 0 |
Reported balance
After 2020-11-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-11-16 · Disposition to issuer · Disposed 5,574 · Balance 0 F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $23.44 · Expires 2022-02-22 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-16 · Disposition to issuer · Disposed 4,266 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F4: These options vested on February 22, 2015. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $30.90 · Expires 2023-03-06 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Disposition to issuer · Disposed 3,236 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F5: These options vested on March 6, 2016. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $55.84 · Expires 2024-03-05 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-16 · Disposition to issuer · Disposed 12,009 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F6: These options vested on March 5, 2017. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $50.66 · Expires 2025-11-17 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-16 · Disposition to issuer · Disposed 16,265 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F7: These options vested on March 4, 2018. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $46.27 · Expires 2026-02-17 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-16 · Disposition to issuer · Disposed 27,314 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F8: These options vested on February 17, 2019. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $45.18 · Expires 2027-03-03 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-16 · Disposition to issuer · Disposed 29,275 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F9: These options vested on March 3, 2020. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $40.97 · Expires 2028-03-02 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-16 · Disposition to issuer · Disposed 29,833 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F10: 9,945 of these options vested on March 2, 2019, 9,944 vested on March 2, 2020 and 9,944 will vest on March 2, 2021. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $27.45 · Expires 2029-03-01 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2020-11-16 · Disposition to issuer · Disposed 27,851 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F15: 9,284 of these options vested on March 2, 2020, 9,283 will vest on March 2, 2021 and 9,284 will vest on March 2, 2022. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $17.48 · Expires 2030-03-02 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2020-11-16 · Disposition to issuer · Disposed 39,361 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F18: 13,121 of these options will vest on March 2, 2021 and 13,120 will vest on each of March 2, 2022 and March 2, 2023. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-11-16 · Disposition to issuer · Disposed 6,102 · Balance 0 F11: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F12: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2020-11-16 · Disposition to issuer · Disposed 31,087 · Balance 0 F11: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F16: Each RSU represents the right to receive one ordinary share of Mylan. 15,543 of the RSUs will vest on March 2, 2021 and 15,544 will vest on March 2, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2020-11-16 · Disposition to issuer · Disposed 73,227 · Balance 0 F11: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F19: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest in three equal annual installments beginning on March 2, 2021. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 30,511 |
Reported balance
After 2020-11-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-11-16 · Grant · Acquired 30,511 · Balance 30,511 F13: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-11-16 · Disposition to issuer · Disposed 30,511 · Balance 0 F14: Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination. F13: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 58,288 |
Reported balance
After 2020-11-16 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2020-11-16 · Grant · Acquired 58,288 · Balance 58,288 F17: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 1, 2019, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2020-11-16 · Disposition to issuer · Disposed 58,288 · Balance 0 F14: Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination. F17: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 1, 2019, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 91,534 |
Reported balance
After 2020-11-16 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2020-11-16 · Grant · Acquired 91,534 · Balance 91,534 F20: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2020, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2020-11-16 · Disposition to issuer · Disposed 91,534 · Balance 0 F14: Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination. F20: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2020, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).
F2: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.
F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination.
F4: These options vested on February 22, 2015.
F5: These options vested on March 6, 2016.
F6: These options vested on March 5, 2017.
F7: These options vested on March 4, 2018.
F8: These options vested on February 17, 2019.
F9: These options vested on March 3, 2020.
F10: 9,945 of these options vested on March 2, 2019, 9,944 vested on March 2, 2020 and 9,944 will vest on March 2, 2021.
F11: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination.
F12: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021.
F13: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination.
F14: Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination.
F15: 9,284 of these options vested on March 2, 2020, 9,283 will vest on March 2, 2021 and 9,284 will vest on March 2, 2022.
F16: Each RSU represents the right to receive one ordinary share of Mylan. 15,543 of the RSUs will vest on March 2, 2021 and 15,544 will vest on March 2, 2022.
F17: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 1, 2019, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination.
F18: 13,121 of these options will vest on March 2, 2021 and 13,120 will vest on each of March 2, 2022 and March 2, 2023.
F19: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest in three equal annual installments beginning on March 2, 2021.
F20: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2020, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2017 Filed Feb 21, 2017 19:02 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 3,531 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-004823 · doc4.xml · derivative · entry 4 Mauro Anthony · CIK 0001534275 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,545 Underlying: Ordinary Shares · 3,531 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 3,531 of the RSUs granted on February 17, 2016 vested on February 17, 2017, 3,530 will vest on February 17, 2018, and 9,015 will vest on February 17, 2019. F2 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 3,531 of the RSUs granted on February 17, 2016 vested on February 17, 2017, 3,530 will vest on February 17, 2018, and 9,015 will vest on February 17, 2019. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 19:02 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 1,152 | $42.05 | $48,441.60 |
DisclosureSEC source: 0000899243-17-004823 · doc4.xml · nonDerivative · entry 2 Mauro Anthony · CIK 0001534275 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,245 F1 · shares: Represents withholding of ordinary shares for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on February 17, 2016. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 19:02 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 3,531 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-004823 · doc4.xml · nonDerivative · entry 1 Mauro Anthony · CIK 0001534275 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.